Bank of Nova Scotia
ATOS icon

Bank of Nova Scotia’s Atossa Therapeutics ATOS Stock Holding History

Bank of Nova Scotia’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,141
Closed -$495K – 1203
2021
Q3 		$495K Sell
10,141
-13,106
-56% -$762K ﹤0.01% 1005
2021
Q2 		$2.2M Buy
+23,247
New +$1.23M ﹤0.01% 799

Other funds holding ATOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of Nova Scotia's ATOS Position: Q4 2021 in Review

Bank of Nova Scotia sold out of Atossa Therapeutics (ATOS) in Q4 2021, closing a stake of 10,141 shares — an estimated $495K sold.

Bank of Nova Scotia first reported a position in ATOS in Q2 2021 and held it in 2 quarters. The position peaked at $2.2M in Q2 2021. 92 funds tracked by Wall St. Rank hold ATOS as of Q4 2021.

  • Bank of Nova Scotia reported no remaining Atossa Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Bank of Nova Scotia sold 10,141 Atossa Therapeutics shares in Q4 2021, an estimated $495K.
  • Bank of Nova Scotia first reported a position in Atossa Therapeutics in Q2 2021 and held it in 2 quarters.
  • Bank of Nova Scotia's Atossa Therapeutics position peaked at $2.2M in Q2 2021.
  • 92 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2021.

Based on Bank of Nova Scotia's 13F filing for Q4 2021, filed 11 Feb 2022.